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Abstract
Background: Liver cancer is a common malignancy with a high mortality rate. Given the poor
prognosis associated with this cancer, many patients seek additional therapies that may improve
quality of life or survival. Several Traditional Chinese Medicines (TCM) have been evaluated in
clinical trials, but little is known about them outside of China.
Methods: We searched independently and in duplicate 8 electronic databases, including 2 Chinese
language databases, until February 2009. We included any randomized clinical trials (RCT)
evaluating a TCM oral preparation for the treatment of hepatocellular cancers. We abstracted data
on survival, tumor response, and performance scores. We conducted a random-effects meta-
analysis and applied a meta-regression analysis.
Results: We included 45 RCTs (n = 3,236). All studies employed an active control group. In
general, the reporting of methodological issues was poor. We analyzed data from 37 trials
reporting on complete response effects score (Relative Risk [RR] of 1.26 (95 CI, 1.04–1.52, P =
0.01, I2 = 0%, P = 0.99). Products containing ginseng, astragalus and mylabris had a larger treatment
effect (OR 1.34, 95% CI, 1.04–1.71, P = 0.01) than the pooled broad estimate, also the case for
astragalus-based treatments (OR 1.35, 95% CI, 1.001–1.80. P = 0.048). We examined survival rates
and pooled 15 studies reporting on 6 month outcomes (RR 1.10, 95% CI, 1.04–1.15, P = < 0.0001,
I2 = 0%, P = 0.60). This effect was consistent at other prospective dates, including 12 months (22
trials, RR 1.26, 95% CI, 1.17–1.36, P = < 0.0001, I2 = 7%, P = 0.36), 24 months (15 trials, 1.72, 95%
CI, 1.40–2.03, P = < 0.0001, I2 = 0%, P = 0.75); and, at 36 months (8 trials, RR 2.40, 95% CI, 1.65–
3.49, P = < 0.0001, I2 = 0%, P = 0.62).
Limitations: All included trials were conducted in China where emerging evidence suggests many
RCTs are not, in fact, randomized. Publication bias may exist, favouring positive reports.
Conclusion: Our meta-analysis displays compelling evidence of effectiveness for hepatocellular
cancers that should be evaluated in high-quality and transparent clinical trials.
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Worldwide, liver cancer is the fifth most common malig-
nancy in men and the eighth in women[1]. According to
the World Health Organization (WHO), liver cancer is a
major health problem and its incidence is increasing[2].
In the United States alone, it is estimated that there will be
22,620 new cases and 18,160 deaths related to liver cancer
in 2009[3].
The major risk factor for liver cancer is the presence of cir-
rhosis of the liver, largely due to chronic hepatitis C virus
(HCV) and hepatitis B virus (HBV) infection[4]. It is
believed that the combined effects of these infections
account for well over 80% of liver cancer cases world-
wide[1]. Through HBV vaccines and screening of blood
and blood products for HBV and HCV, primary liver can-
cer is the first human cancer largely amenable to preven-
tion[1].
With respect to treatment, the plan depends on a number
of factors, including the extent of the disease, growth pat-
tern of the tumour and hepatic functional reserve of the
patient[5]. In cases of localized resectable liver tumours,
standard treatment is surgical resection (partial hepatec-
tomy) in patients without liver cirrhosis and surgical
resection or liver transplantation in patients with liver cir-
rhosis[5]. In cases of localized non-resectable liver
tumours, the standard treatment of total hepatectomy
with liver transplantation is considered first followed by
other options, including chemoembolization, percutane-
ous ethanol injection, radiofrequency ablation, inclusion
in clinical trials or systemic chemotherapy (anthracy-
clines, cisplatin and 5-FU)[5]. Systematic chemotherapy,
however, is reported to have a 10% response rate and no
survival benefit[5]. In cases of advanced liver tumours,
there is no established standard of care[5].
Given the poor prognosis associated with some liver can-
cers and limited treatment options outside of surgery,
patients may seek alternative treatments, including tradi-
tional Chinese medicine (TCM) products, alone or in
combination with standard of care. The purpose of this
study is to systematically review and meta-analyze data
from randomized clinical trials (RCTs) for evidence on
the efficacy of TCM products in the treatment of liver can-
cer.
Methods
Search strategy, trials selection, and data retrieval
To be eligible for inclusion in our systematic review, stud-
ies had to have enrolled adult patients (>18 years) with
liver cancer. The patients had to be randomly allocated to
an active TCM formulation treatment or a control group
with either placebo or no treatment. In addition, any co-
intervention had to be the same in both groups except for
the TCM formulation. We excluded studies that reported
only laboratory values rather than clinical responses. We
also excluded direct comparisons of TCM formulations.
PW and EM worked independently, in duplicate, search-
ing the following English electronic databases: MEDLINE
(1966–February 2009), AMED (1985–February 2009),
Alt Health Watch (1995–February 2009), CINAHL
(1982–February 2009), Nursing and Allied Health Collec-
tion: Basic (1985–February 2009), Cochrane Database of
Systematic Reviews (2008). In addition, PW, and YL, flu-
ent in Mandarin and Cantonese, searched the Chinese
database CNKI (1979–February 2009) and Wan Fang
(1994–February 2009) independently. No language
restrictions were placed on the searches.
Three reviewers (PW, EM and JL) assessed eligibility based
on the full text papers and conducted data extraction,
independently, using a standard pre-piloted form. Disa-
greements were resolved by consensus or by a third
reviewer. If the required information was not available in
the published article, we obtained additional information
in correspondence with the authors. We included all eval-
uated outcome measures including: disease stage, Karnof-
sky performace (KP), the Child-Pugh score and the
response evaluation criteria in solid tumors (RECIST). The
response is categorized as complete response (CR), partial
response (PR) outcomes, stable disease (SD), progressive
disease (PD) and as CR + PR as a proportion for response
rate (RR). We additionally examined survival rates by
group according to 6, 12, 18, 24, 36 and 60-month sur-
vival rates, where reported.
In addition, we extracted data on trial quality, protocol,
and outcomes assessed. We assessed quality through the
reporting of the following criteria: sequence generation,
allocation concealment, reporting of who was blinded,
adequate descriptions of patient withdrawal, language of
publication, and exposure to chemotherapy. We also
noted the language in which the paper was written and the
setting the studies were conducted. These criteria were not
used for weighting covariates in the meta-analysis;
instead, these were considered a priori explanations for
study heterogeneity.
Statistical analysis
We applied the Relative Risk and 95% Confidence Inter-
vals as our primary effect measure in this analysis. For
analysis examining response and survival, favourable
results for the TCM intervention are in the direction
greater than 1. In circumstances of zero outcome events in
either arm of a trial, we used the Haldane method and
added 1 to each arm, as suggested by Sheehe[6]. We first
pooled studies on all interventions versus all controls
using the DerSimonian-Laird random effects method[7].Page 2 of 13
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of all potential studies, and incorporates an additional
between-study component to the estimate of variability.
We calculated the I2 statistic for each analysis as a measure
of the proportion of the overall variation that is attributa-
ble to between-study heterogeneity[8]. Forest plots are
displayed for the primary analysis, showing individual
study effect measures with 95% CIs and the overall Der-
Simmonian-Laird pooled estimate. We conducted a meta-
regression analysis using the unrestricted maximum like-
lihood method to determine if the a priori covariates of
TCM formulation yielded differing effects. We examined
publication bias visually and through the Begg-Mazum-
dar, Egger, and Horbold-Egger tests. We calculated the
optimal information size (OIS) required to determine
adequate power across trials. We used Stats Direct and
Comprehensive Meta-Analysis (Version 2) for all statisti-
cal procedures. All p-values are 2-sided and a p-value <
0.05 was considered significant. PW and EM conducted
the analysis.
Results
Our extensive searching yielded 130 titles and/or
abstracts, of which 54 were found likely to be relevant.
Nine of the full text articles reviewed were excluded for
one of two reasons: 1) either the study was not rand-
omized; 2) TCM was the control intervention 3)study was
duplicated.
In total, 45 publications [9-53] containing independent
data fit the criteria for inclusion. Figure 1 details the liter-
ature retrieval process used during our searches and the
rationales for exclusion leading to the final selection.
Among the final 45 studies, 44 [9-14,16-53]were pub-
lished in Chinese languages and 1 [15]was published in
English. All the studies were conducted in China.
Characteristics of included studies
The 45 RCTs included 3,236 patients, 1,682 in the treat-
ment groups and 1,554 in the control groups (See Addi-
tional file 1 and 2). Most trials were small and the median
intervention group size was 32 (interquartile range [IQR]
30–42) and control group size is 31 (IQR 30–38). The
majority of trials (24)[9,12,13,15-18,25,27,29,30,32,34-
36,40,46,47,49-54] included patients with stage II or
more advanced cancers. Additional file 1 displays the
study characteristics and formulations along with the
TCM philosophy for the preparation. All studies
employed transcatheter arterial chemoembolization
(TACE) as adjunct therapy. No placebo was used as the
control group in any study.
TCM Interventions
The TCM interventions identified in this study were prin-
cipally combinations of different herbal medicines or ani-
mal/insect extracts (Additional file 1). A brief outline on
the oncologic and immunologic pharmacology of the
most commonly used ingredients is presented below.
Astragalus
Astragalus appears to have a number of immunomodula-
tory properties [55-57]. Astragalus appears to have anti-
tumour activity where its potentiates LAK cell activity in
vitro when used in combination with IL-2[58]. Astragalus
appears to restore in vitro T-cell function, which is sup-
pressed in cancer patients[59].
Panax ginseng
Panax ginseng and its chemical constituents were found to
have inhibitory effects on putative carcinogenesis mecha-
nisms, e.g., cell proliferation and apoptosis, immunosur-
veillance and angiogenesis[60]. Ginsenosides from Panax
ginseng have been shown to inhibit tumor cell invasion
and to suppress sister chromatid exchanges in human
lymphocytes[61].
Toad skin secretions (bufotoxin)
The toad skin secretion bufalin was found to induce apop-
tosis in human-leukemia cells by altering expression of
apoptotic genes c-myc and bcl-2[62]. Other toad skin
secretions like 3-formyloxyresibufogenin, 19-oxobufalin,
19-oxodesacetylcinobufagin, 6-hydroxycinobufagin and
1-hydroxybufalin were found to exert inhibitory effects on
KB, HL-60 and MH-60 cancer cell lines[63].
Beetle extracts (Mylabris)
An extract from Mylabris phaleratais, the dried body of the
Chinese blister beetle, was shown to have anti-cancer
activity via inducing cancer cell apoptosis and was associ-
ated with little toxicity[64].
Atractylodes
Atractylodes appears to have anticancer activity by induc-
ing apoptosis and cytotoxic effects against leukemia and
other cancer cell lines[65].
Bupleurum
Saikosaponins from Bupleurum falcatum were shown to
exhibit potent anti-cell adhesive activity on solid tumour
cells and to have strong hemolytic action[66].
Curcuma
Curcuma longa may have immunostimulatory activity[67].
Meta-analysis
Complete Response
We analyzed data from 37 trials[10,12,13,15-
18,20,21,23,25-30,32,33,35,36,38-41,44-54,68,69]
reporting on RECIST CR score. Our pooled analysis indi-
cates an RR of 1.26 (95 CI, 1.04–1.52, P = 0.01, I2 = 0%, PPage 3 of 13
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Flow diagram of included studiesigure 1
Flow diagram of included studies.
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that products containing ginseng, astragalus and mylabris
had a larger treatment effect (OR 1.34, 95% CI, 1.04–
1.71, P = 0.01) than the pooled broad estimate and that
any product containing astragalus also had this effect (OR
1.35, 95% CI, 1.001–1.80. P = 0.048).
Partial response
We pooled data from 37 trials [10,12,13,15-
18,20,21,23,25-30,32,33,35,36,38-41,44-54,68,69]
reporting on PR between groups. The pooled RR is 1.27
(95% CI, 1.17–1.38, P = < 0.0001, I2 = 0%, P = 0.99, See
Figure 3). When we examined if differential effects existed
across specific formulations, we found that studies using
bufotoxin demonstrated increased effects (OR 1.25, 95%
CI, 1.15–1.37, P = < 0.0001), as did studies using ginseng,
astragalus and mylabris (OR 1.27, 95% CI, 1.16–1.39, P =
< 0.0001) and any product using astragalus (OR 1.27,
1.13–1.42, P = < 0.0001).
Stable disease
We pooled data from 37 trials[10-13,15-18,20,21,23,25-
30,32,33,35,36,38-40,44-54,68,69] reporting on stable
disease between groups at study conclusion. The pooled
RR is 1.03 (95% CI, 0.93–1.15, P = 0.47, I2 = 10%, P =
0.29, see figure 4). When we examined the effects of dif-
ferent preparations we did not show an effect with bufo-
toxin (OR 1.04, 95% CI, 0.95–1.15, P = 0.35), with
Forest-plot of complete responseigure 2
Forest-plot of complete response.Page 5 of 13
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1.14, P = 0.40) or any product using astragalus (OR 1.02,
10.92–1.13, P = 0.63).
Progressive disease
We pooled data from 37 trials[11-13,15-18,20,21,23,25-
30,32,33,35,36,38-40,44-54,68-70] reporting on progres-
sive disease among patients. We found an inflated pro-
gressive disease rate in the control groups (RR 0.54, 95%
CI, 0.45–0.64, P = < 0.0001, I2 = 0%, P = 0.66, see figure
5). Studies utilizing bufotoxin had a decreased risk (OR
0.54, 95% CI, 0.46 to -0.65, P = < 0.0001), this was also
the case with studies using ginseng, astragalus and
mylabris (0.54, 95% CI, -0.46 to -0.66, P = < 0.0001) and
with studies using any form of astragalus (OR 0.57, 95%
CI, 0.46 to -0.70, P = < 0.0001).
Forest plot of partial responseigure 3
Forest plot of partial response.Page 6 of 13
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We examined survival rates and pooled 15 stud-
ies[12,17,25,26,28,29,33,36,42,44,46,50,54,69,70]
reporting on 6 month outcomes (RR 1.10, 95% CI, 1.04–
1.15, P = < 0.0001, I2 = 0%, P = 0.60). This effect was con-
sistent at other prospective dates, including 12 months
(22 trials[9,12,17,20,25-29,31,33,35,36,41,42,44,46,47,
50,54,69,70], RR 1.26, 95% CI, 1.17–1.36, P = < 0.0001,
I2 = 7%, P = 0.36, See figure 6); 18 months (4 tri-
als[9,26,28,52], RR 1.71, 95% CI, 1.002–2.91, P = 0.049,
I2 = 70%, P = 0.009); 24 months (15 trials[17,20,26-
28,31,33,36,41,42,46,52,54,69,70], 1.72, 95% CI, 1.40–
2.03, P = < 0.0001, I2 = 0%, P = 0.75); and, at 36 months
(8 trials[27,31,33-35,42,47,69], RR 2.40, 95% CI, 1.65–
3.49, P = < 0.0001, I2 = 0%, P = 0.62). We applied meta-
regression on the 12 month survival and found increased
effect with bufotoxin (OR 1.22, 95% CI, 1.13–1.32, P = <
0.0001) and with products containing ginseng, astragalus
Forest plot of stabilized diseaseigure 4
Forest plot of stabilized disease.Page 7 of 13
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and astragalus alone (OR 1.28, 95% CI, 1.15–1.40, P = <
0.0001).
Symptom improvement
Several studies reported on improvement of symptoms. In
particular, 6 studies[13,15,23,29,44,68] reported on
abdominal pain improvements favouring TCM
approaches (RR 1.50, 95% CI, 1.09–2.07, P = 0.013,
I244%, P = 0.11). Abdominal distension did not improve
among TCM recipients in 5 reported trials8,18,24,39,50 (RR
1.26, 95% CI, 0.96–1.64, P = 0.09, I2 = 4%, P = 0.38).
Fatigue significantly improved in 4 reported trials8,18,24,39,
(RR 1.54, 95% CI, 1.17–2.01, P = 0.001, I2 = 0%, P =
0.87), and appetite improved in 4 reported trials8,18,24,39,
Forest plot of progressive diseaseigure 5
Forest plot of progressive disease.Page 8 of 13
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Optimal Information Size (OIS)
Almost all trials included in our analysis were small. We
applied OIS based on the event rate in the intervention
and control arms for the PR outcome. We found an event
rate of 0.42 in the intervention arms and an event rate of
0.33 in the control arms. When applying 80% power and
a two-tailed 5% alpha, we identify that we require at least
906 participants in our meta-analysis.
Publication bias
We assessed publication bias visually with a funnel plot
and applied several statistical tests to determine the likeli-
hood of publication bias. We found no vidence when
applying the Begg-Mazumdar test (P = 0.14), Egger's test
(P = 0.80) or Horbold-Egger's test (P = 0.89). We also
imputed the number of studies that were likely missing,
but the resulting number was unconcerning (n = 2) and
was unlikely to change the effect estimate.
Discussion
We found consistent effects of traditional Chinese medi-
cines when combined with TACE versus TACE alone. The
majority of studies included in our analysis were small or
of moderate size and none can provide definitive answers
on treatment options, although compelling results related
to bufotoxin, astragalus and products containing ginseng,
astragalus and mylabris warrant further examination. Our
Forest plot of 12-months survivaligure 6
Forest plot of 12-months survival.Page 9 of 13
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lish languages may have on identifying potentially useful
new interventions for common diseases. While our study
finds compelling results, there is also reason for caution,
given the poor reporting of clinical trials in China. Only
independently conducted research from high-quality
research teams will strengthen the inference of effective-
ness.
Strengths of our study include our extensive searches of
literature in both English and in Chinese languages, and
using Chinese language databases for our search. Two of
us (PW, JL) understand and read Mandarin and Canton-
ese, along with English, thus allowing searches across sev-
eral languages. We applied a broad criteria for pooling
studies. We included any TCM formulation and then con-
ducted a meta-regression analysis to determine if specific
preparation yielded differing effects over the broad group,
and in several cases did.
Limitations of our study include the underlying concern
about the quality of the included studies. As we highlight,
the majority of studies were small, with typically 30 par-
ticipants per arm. Meta-analysis aims to overcome issues
of power through pooling, thus increasing sample size
and power. We applied an OIS on the overall event rate of
partial response and found that a pooled sample size of
1,108 provided sufficient evidence of an effect. This did
not apply to specific formulations. We further assessed
issues of methodological rigour as two major concerns
with Chinese-based clinical trials. Firstly, is that only pos-
itive trials are published in Chinese medical journals, and
second, is that some trials reported as randomized are, in
fact, not randomized. A recent evaluation by Wu et al.
found that many studies labelled as RCTs with Chinese
journals were, in fact, not randomized[71] In our own
experience, we recognize many Chinese clinical trialists
have not been exposed to appropriate clinical epidemiol-
ogy training. We examined publication bias through both
visual inspection of the funnel plot on the primary out-
come (PR) and through statistical tests, but were unable to
identify publication bias. However, funnel plots cannot
rule out publication bias and we remain cautious that
many negative trials likely exist.
From a clinical standpoint, the results of this study are
very encouraging but should be implemented with cau-
tion. The average clinician will be reassured that TCM
interventions, both herbal-based and animal/insect-
based, were safely combined with chemotherapy. The
average clinician, however, likely will not scrutinize the
results of this study using evidence-based principles and
may implement our findings into practice due to the over-
whelming positive response in our meta-analysis. Given
this tendency, the results from this study should be care-
fully disseminated to the medical community with the
caveat that although promising, our findings need to be
confirmed via a RCT conducted in a Western academic set-
ting.
Our study may prove useful for a number of reasons.
Firstly, there is reason to further examine the evidence of
several of the interventions included in our analysis.
Other investigators have examined the role of herbal med-
icines and TCM interventions for hepatocellular cancers,
lung cancers and hepatitis and found compelling evidence
in humans [72-75] However, perhaps a far more impor-
tant finding from our analysis and approach is the role
that searching for clinical trials in non-English languages
may play in drug discovery. Important first line drugs,
such as artemisin-based therapies for malaria, have been
discovered through searching existing trials in non-Eng-
lish languages. [76]
There have now been two studies prior to ours that exam-
ined the role of TCM interventions on survival and clinical
outcomes in patients also receiving TACE. [72,75] The
first study, by Shu et al[72], published in 2005, included
26 RCTs of interventions including 2079 patients. Similar
to ours, they found improved survival at 12 months [RR
1.55, 95% CI, 1.39–1.72], at 24 months [RR 2.15, 95% CI,
1.75–2.64], and at 36 months [RR, 2.76, 95% CI, 1.95–
3.91]. Tumor response was also significantly increased
[RR 1.39, 95% CI, 1.24–1.56]. A more recent study, pub-
lished in 2009 by Cho and Chen, [75] included 30 studies
including 2428 patients. As with ours, they found
increased survval at 12 months [OR 1.92, 95% CI, 1.43–
2.57], at 24 months [OR 3.55, 95% CI, 2.36–5.36], and at
36 months [OR 5.12, 95% CI, 2.76–9.52]. The inflated
effect sizes found in the study by Cho and Chen may be
related to their choice of effect size of OR rather than the
more conservative RR((([77] Given that all three reviews
found compelling evidence of a role for TCM in hepato-
cellular cancers, it seems appropriate that further evalua-
tions, in a non-Chinese setting, occur in order to
determine if we have a possible new opportunity for drug
development.
Our study builds on the findings of others about the het-
erogeneous quality of randomized trials from China. In
our own experience in China, we have doubts that many
methodological features attributed to randomized trials,
were in fact conducted. A previous analysis, by Vickers et
al, found that most trials conducted in China were
reported as positive,[78] a finding our analysis also
supports8. While several explanations for this phenome-
non exist, a likely explanation is the slow uptake of evi-
dence-based medicine and clinical trials methodology in
academic research centres[79] With the opening of thePage 10 of 13
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ology will receive considerably more attention[80]
In conclusion, our study provides important inferences
about new potential therapeutic options for hepatocellu-
lar cancers. While these finds are compelling, there is a
need for confirmation of these studies in well-conducted
RCTs conducted in Western settings. Until such time,
potentially useful interventions cannot be wholly recom-
mended based on evidence alone.
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